Mylan Pharmaceuticals Inc. is liable for infringing one of Regeneron Pharmaceutical Inc.'s patents for a protein antagonist used in Eylea, a drug Regeneron makes to treat eye conditions, a federal judge ruled on Wednesday.
Chief Judge Thomas S. Kleeh, of the US District Court for the Northern District of West Virginia, said Regeneron showed Mylan had infringed its ‘865 patent. The patent is estimated to expire in 2027.
Kleeh also said Mylan infringed some claims in its ‘572 and ‘601 patents, but those claims were obvious and, therefore, invalid. The court’s reasoning in support of the judgment is still under ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.